<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321800</url>
  </required_header>
  <id_info>
    <org_study_id>1409R2121</org_study_id>
    <nct_id>NCT02321800</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections</brief_title>
  <acronym>APEKS-cUTI</acronym>
  <official_title>A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the efficacy and safety of intravenous cefiderocol
      (S-649266) in hospitalized adults with complicated urinary tract infections caused by
      Gram-negative pathogens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2015</start_date>
  <completion_date type="Actual">August 16, 2016</completion_date>
  <primary_completion_date type="Actual">July 26, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure</measure>
    <time_frame>Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)</time_frame>
    <description>The primary efficacy endpoint was the composite outcome of clinical response and microbiological response at the test of cure assessment, defined as 7 days (±2 days) after the end of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment</measure>
    <time_frame>Early assessment (EA; Day 4)</time_frame>
    <description>A composite outcome of clinical response and microbiological response at the early assessment, defined as Day 4 of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment</measure>
    <time_frame>End of treatment (EOT; Day 7 to 14)</time_frame>
    <description>A composite outcome of clinical response and microbiological response at the end of treatment, defined as the end of the last infusion of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up</measure>
    <time_frame>Follow-up (FUP; 14 days after end of treatment, Day 21 to 28)</time_frame>
    <description>A composite response of clinical response and microbiological response at the follow-up assessment, defined as 14 days after the end of treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug.
Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, showed that the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at Test of Cure</measure>
    <time_frame>Test of cure (7 days after end of treatment, Day 14 to 21)</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at Early Assessment</measure>
    <time_frame>Early assessment, Day 4</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at End of Treatment</measure>
    <time_frame>End of treatment, Day 7 to 14</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at Follow-up</measure>
    <time_frame>Follow-up, 14 days after end of treatment, Day 21 to 28</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen</measure>
    <time_frame>Test of cure; 7 days after end of treatment, Day 14 to 21</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen</measure>
    <time_frame>Early assessment, Day 4</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen</measure>
    <time_frame>End of treatment, Day 7 to 14</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen</measure>
    <time_frame>Follow-up, 14 days after the end of treatment, Day 21 to 28</time_frame>
    <description>Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Test of Cure</measure>
    <time_frame>Test of cure, 7 days after end of treatment, Day 14 to 21</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Early Assessment</measure>
    <time_frame>Early assessment, Day 4</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at End of Treatment</measure>
    <time_frame>End of treatment, Day 7 to 14</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Follow-up</measure>
    <time_frame>Follow-up, 14 days after end of treatment, Day 21 to 28</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI showing no evidence of recurrence after administration of the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Test of Cure Per Uropathogen</measure>
    <time_frame>Test of cure, 7 days after end of treatment, Day 14 to 21</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Early Assessment Per Uropathogen</measure>
    <time_frame>Early assessment, Day 4</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at End of Treatment Per Uropathogen</measure>
    <time_frame>End of treatment, Day 7 to 14</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Follow-up Per Uropathogen</measure>
    <time_frame>Follow-up, 14 days after the end of treatment, Day 21 to 28</time_frame>
    <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Cefiderocol</measure>
    <time_frame>On Day 3 of dosing prior to infusion, end of infusion, and at 1 hour post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Concentration of Cefiderocol</measure>
    <time_frame>Day 3, 2 hours and 6 hours after end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From first dose of study drug until 28 days after end of treatment; Day 35 to 42</time_frame>
    <description>A serious adverse event was defined by regulation as any adverse event (AE) occurring at any dose that resulted in any of the following outcomes:
Death
Life-threatening condition
Hospitalization or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Congenital anomaly/birth defect
Other medically important condition.
The relationship of an event to the study drug was determined by the investigator based on whether the AE could be reasonably explained as being caused by the study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">452</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Cefiderocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipenem/cilastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefiderocol</intervention_name>
    <description>2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (&lt; 70 kg) included every 6-hour dosing intervals and/or reduced doses.</description>
    <arm_group_label>Cefiderocol</arm_group_label>
    <other_name>FETROJA®</other_name>
    <other_name>S-649266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem/cilastatin</intervention_name>
    <description>1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (&lt; 70 kg) included every 6-hour dosing intervals and/or reduced doses.</description>
    <arm_group_label>Imipenem/cilastatin</arm_group_label>
    <other_name>PRIMAXIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized male and female patients ≥ 18 years

          -  Clinical diagnosis of either complicated urinary tract infections (cUTI) with or
             without pyelonephritis or acute uncomplicated pyelonephritis

          -  cUTI diagnosed with a history of ≥ 1 of the following:

               -  Indwelling urinary catheter or recent instrumentation of the urinary tract

               -  Urinary retention (caused by benign prostatic hypertrophy)

               -  Urinary retention of at least 100 mL or more of residual urine after voiding
                  (neurogenic bladder)

               -  Obstructive uropathy

               -  Azotemia caused by intrinsic renal disease (blood urea nitrogen and creatinine
                  values greater than normal laboratory values) OR Pyelonephritis and normal
                  urinary tract anatomy, ie, acute uncomplicated pyelonephritis AND

        At least 2 of the following signs or symptoms:

          -  Chills or rigors or warmth associated with fever (temperature greater than or equal to
             38 degrees Celsius)

          -  Flank pain (pyelonephritis) or suprapubic/pelvic pain (cUTI)

          -  Nausea or vomiting

          -  Dysuria, urinary frequency, or urinary urgency

          -  Costo-vertebral angle tenderness on physical examination AND

        All subjects had to have urinalysis evidence of pyuria demonstrated by 1 of the following:

          -  Dipstick analysis positive for leukocyte esterase

          -  ≥ 10 white blood cells (WBCs) per μL in unspun urine, or ≥ 10 WBCs per high power
             field in spun urine

               -  Positive urine culture within 48 hours prior to randomization containing ≥10^5
                  colony forming unit (CFU)/mL of a Gram-negative uropathogen likely to be
                  susceptible to imipenem (IPM)

               -  Patients who were treated previously with an empiric antibiotic other than the
                  study drugs but failed treatment, both clinically and microbiologically, were
                  eligible for the study if they had an identified Gram-negative uropathogen that
                  was not susceptible to the previously used empiric treatment and likely to be
                  susceptible to IPM

               -  Subjects receiving antibiotic prophylaxis for UTI who present with signs and
                  symptoms consistent with an active new UTI

        Exclusion Criteria:

          -  Urine culture identifies only a Gram-positive pathogen and/or a Gram-negative
             uropathogen resistant to IPM

          -  Urine culture at study entry isolates more than 2 uropathogens or patient has a
             confirmed fungal UTI

          -  Asymptomatic bacteriuria, the presence of &gt;10^5 CFU/mL of a uropathogen and pyuria but
             without local or systemic symptoms

          -  Patient is receiving hemodialysis or peritoneal dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.</citation>
    <PMID>30509675</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <results_first_submitted>November 20, 2019</results_first_submitted>
  <results_first_submitted_qc>November 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2019</results_first_posted>
  <disposition_first_submitted>July 11, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 13, 2017</disposition_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S-649266</keyword>
  <keyword>complicated urinary tract infection</keyword>
  <keyword>cefiderocol</keyword>
  <keyword>acute uncomplicated pyelonephritis</keyword>
  <keyword>Gram-negative pathogens</keyword>
  <keyword>imipenem/cilastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 67 hospitals in 15 countries. Participants diagnosed with complicated urinary tract infections (cUTIs) with or without pyelonephritis or acute uncomplicated pyelonephritis were enrolled from February 5, 2015 to August 16, 2016.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned (2:1) to receive either cefiderocol or imipenem-cilastatin. Randomization was stratified by clinical diagnosis (complicated urinary tract infection with or without pyelonephritis or with acute uncomplicated pyelonephritis) and region (North America, Europe, Russia, and Japan).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cefiderocol</title>
          <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Imipenem/Cilastatin</title>
          <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified intent-to-treat population includes all randomly assigned participants who received at least one dose of study drug and had qualifying Gram-negative uropathogen (≥1 × 10⁵ colony forming unit (CFU)/mL)</population>
      <group_list>
        <group group_id="B1">
          <title>Cefiderocol</title>
          <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Imipenem/Cilastatin</title>
          <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="252"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="371"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="252"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="16.10"/>
                    <measurement group_id="B2" value="61.3" spread="18.48"/>
                    <measurement group_id="B3" value="62.0" spread="16.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="252"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="252"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="252"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="252"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine Clearance Renal Grading Group</title>
          <description>Creatinine clearance was calculated using the Cockcroft-Gault formula ([140 − age in years] × [weight in kg])/(72 × serum creatinine in mg/dL [multiplied by 0·85 for women]) using data from the central laboratory.</description>
          <population>Participants with available data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&gt; 80 mL/min (Normal)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 50 - 80 mL/min (Mild)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 - 50 mL/min (Moderate)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt; 30 mL/min (Severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Diagnosis at Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="252"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>cUTI with pyelonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>cUTI without pyelonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acute Uncomplicated Pyelonephritis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Gram-negative Uropathogens &gt; 10⁵ CFU/mL Isolated at Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="252"/>
                    <count group_id="B2" value="119"/>
                    <count group_id="B3" value="371"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>1 uropathogen</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 uropathogens</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure</title>
        <description>The primary efficacy endpoint was the composite outcome of clinical response and microbiological response at the test of cure assessment, defined as 7 days (±2 days) after the end of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
        <time_frame>Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure</title>
          <description>The primary efficacy endpoint was the composite outcome of clinical response and microbiological response at the test of cure assessment, defined as 7 days (±2 days) after the end of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6"/>
                    <measurement group_id="O2" value="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The margin of noninferiority was 20%. Noninferiority was concluded if the lower bound of a 2-sided 95% CI for the difference in response rates between the 2 treatment groups was greater than -20%. If the noninferiority inference based on the 20% margin was concluded successfully, noninferiority inference based on the 15% margin was performed.</non_inferiority_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>18.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.23</ci_lower_limit>
            <ci_upper_limit>28.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment</title>
        <description>A composite outcome of clinical response and microbiological response at the early assessment, defined as Day 4 of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
        <time_frame>Early assessment (EA; Day 4)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment</title>
          <description>A composite outcome of clinical response and microbiological response at the early assessment, defined as Day 4 of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                    <measurement group_id="O2" value="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.48</ci_lower_limit>
            <ci_upper_limit>7.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment</title>
        <description>A composite outcome of clinical response and microbiological response at the end of treatment, defined as the end of the last infusion of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
        <time_frame>End of treatment (EOT; Day 7 to 14)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at End of Treatment</title>
          <description>A composite outcome of clinical response and microbiological response at the end of treatment, defined as the end of the last infusion of antibiotic treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.
Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                    <measurement group_id="O2" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.48</ci_lower_limit>
            <ci_upper_limit>4.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up</title>
        <description>A composite response of clinical response and microbiological response at the follow-up assessment, defined as 14 days after the end of treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug.
Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, showed that the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.</description>
        <time_frame>Follow-up (FUP; 14 days after end of treatment, Day 21 to 28)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Follow-up</title>
          <description>A composite response of clinical response and microbiological response at the follow-up assessment, defined as 14 days after the end of treatment.
Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug.
Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, showed that the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                    <measurement group_id="O2" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>15.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.69</ci_lower_limit>
            <ci_upper_limit>25.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at Test of Cure</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
        <time_frame>Test of cure (7 days after end of treatment, Day 14 to 21)</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at Test of Cure</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0"/>
                    <measurement group_id="O2" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>17.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.92</ci_lower_limit>
            <ci_upper_limit>27.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at Early Assessment</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
        <time_frame>Early assessment, Day 4</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at Early Assessment</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.83</ci_lower_limit>
            <ci_upper_limit>7.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at End of Treatment</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
        <time_frame>End of treatment, Day 7 to 14</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at End of Treatment</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as all bacterial uropathogens found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8"/>
                    <measurement group_id="O2" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.04</ci_lower_limit>
            <ci_upper_limit>5.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at Follow-up</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.</description>
        <time_frame>Follow-up, 14 days after end of treatment, Day 21 to 28</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at Follow-up</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen(s) identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>13.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.21</ci_lower_limit>
            <ci_upper_limit>24.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>Test of cure; 7 days after end of treatment, Day 14 to 21</time_frame>
        <population>Modified intent-to-treat population with the relevant pathogen at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at Test of Cure Per Uropathogen</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Modified intent-to-treat population with the relevant pathogen at Baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>Early assessment, Day 4</time_frame>
        <population>Intent-to-treat population with the relevant pathogen at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at Early Assessment Per Uropathogen</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Intent-to-treat population with the relevant pathogen at Baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                    <measurement group_id="O2" value="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6"/>
                    <measurement group_id="O2" value="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>End of treatment, Day 7 to 14</time_frame>
        <population>Modified intent-to-treat population with the relevant pathogen at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at End of Treatment Per Uropathogen</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with eradication defined as the bacterial pathogen found at study entry at &gt; 1 × 10⁵ CFU/mL reduced to 1 × 10⁴ CFU/mL or less.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Modified intent-to-treat population with the relevant pathogen at Baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9"/>
                    <measurement group_id="O2" value="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen</title>
        <description>Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>Follow-up, 14 days after the end of treatment, Day 21 to 28</time_frame>
        <population>Modified intent-to-treat population with the relevant pathogen at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Microbiological Eradication at Follow-up Per Uropathogen</title>
          <description>Microbiological outcome was based on quantitative microbiological urine cultures, with sustained eradication defined as a urine culture obtained after documented eradication at the TOC, up to and including the FUP, where the bacterial uropathogen identified at baseline at ≥ 10⁵ CFU/mL remained &lt; 10⁴ CFU/mL.
Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Modified intent-to-treat population with the relevant pathogen at Baseline</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9"/>
                    <measurement group_id="O2" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Test of Cure</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
        <time_frame>Test of cure, 7 days after end of treatment, Day 14 to 21</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Test of Cure</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.66</ci_lower_limit>
            <ci_upper_limit>9.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Early Assessment</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
        <time_frame>Early assessment, Day 4</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Early Assessment</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5"/>
                    <measurement group_id="O2" value="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.57</ci_lower_limit>
            <ci_upper_limit>6.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at End of Treatment</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
        <time_frame>End of treatment, Day 7 to 14</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at End of Treatment</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0"/>
                    <measurement group_id="O2" value="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.42</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Follow-up</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI showing no evidence of recurrence after administration of the last dose of study drug.</description>
        <time_frame>Follow-up, 14 days after end of treatment, Day 21 to 28</time_frame>
        <population>Modified intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Follow-up</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI showing no evidence of recurrence after administration of the last dose of study drug.</description>
          <population>Modified intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3"/>
                    <measurement group_id="O2" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjusted estimates of the difference between the two treatment groups are based on a stratified analysis using Cochran-Mantel-Haenszel weights, with clinical diagnosis (complicated urinary tract infection with or without pyelonephritis vs acute uncomplicated pyelonephritis) as the stratification factor.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Treatment Difference</param_type>
            <param_value>9.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>18.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Test of Cure Per Uropathogen</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>Test of cure, 7 days after end of treatment, Day 14 to 21</time_frame>
        <population>Modified intent-to-treat population with the relevant pathogen at Baseline and available clinical outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Test of Cure Per Uropathogen</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Modified intent-to-treat population with the relevant pathogen at Baseline and available clinical outcome data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1"/>
                    <measurement group_id="O2" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Early Assessment Per Uropathogen</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>Early assessment, Day 4</time_frame>
        <population>Modified intent-to-treat population with the relevant pathogen at Baseline and with available clinical outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Early Assessment Per Uropathogen</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Modified intent-to-treat population with the relevant pathogen at Baseline and with available clinical outcome data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8"/>
                    <measurement group_id="O2" value="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at End of Treatment Per Uropathogen</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>End of treatment, Day 7 to 14</time_frame>
        <population>Modified intent-to-treat population with the relevant pathogen at Baseline and with available clinical outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at End of Treatment Per Uropathogen</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with response defined as resolution or improvement of complicated urinary tract infection symptoms present at study entry and the absence of new symptoms. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Modified intent-to-treat population with the relevant pathogen at Baseline and with available clinical outcome data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9"/>
                    <measurement group_id="O2" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Follow-up Per Uropathogen</title>
        <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
        <time_frame>Follow-up, 14 days after the end of treatment, Day 21 to 28</time_frame>
        <population>Modified intent-to-treat population with the relevant pathogen at Baseline and with available clinical outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Follow-up Per Uropathogen</title>
          <description>Clinical response was based on the investigator's evaluation of the participant's clinical signs and symptoms, with sustained response defined as all pre-therapy signs and symptoms of cUTI show no evidence of recurrence after administration of the last dose of study drug. Results are reported for the 4 most frequent uropathogens, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus mirabilis.</description>
          <population>Modified intent-to-treat population with the relevant pathogen at Baseline and with available clinical outcome data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Escherichia coli</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Klebsiella pneumoniae</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas aeruginosa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proteus mirabilis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Cefiderocol</title>
        <time_frame>On Day 3 of dosing prior to infusion, end of infusion, and at 1 hour post infusion</time_frame>
        <population>The pharmacokinetic (PK) concentration population included all participants who underwent plasma or urine PK sampling and had at least 1 evaluable PK assay result for cefiderocol</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Cefiderocol</title>
          <population>The pharmacokinetic (PK) concentration population included all participants who underwent plasma or urine PK sampling and had at least 1 evaluable PK assay result for cefiderocol</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" spread="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after end of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Concentration of Cefiderocol</title>
        <time_frame>Day 3, 2 hours and 6 hours after end of infusion</time_frame>
        <population>Pharmacokinetic concentration population with available urine concentration data</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Concentration of Cefiderocol</title>
          <population>Pharmacokinetic concentration population with available urine concentration data</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours after end of infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2710" spread="1520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours after end of infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1520" spread="1370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>A serious adverse event was defined by regulation as any adverse event (AE) occurring at any dose that resulted in any of the following outcomes:
Death
Life-threatening condition
Hospitalization or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Congenital anomaly/birth defect
Other medically important condition.
The relationship of an event to the study drug was determined by the investigator based on whether the AE could be reasonably explained as being caused by the study drug.</description>
        <time_frame>From first dose of study drug until 28 days after end of treatment; Day 35 to 42</time_frame>
        <population>The safety population included all randomized participants who received at least 1 dose of the study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cefiderocol</title>
            <description>Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Imipenem/Cilastatin</title>
            <description>Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>A serious adverse event was defined by regulation as any adverse event (AE) occurring at any dose that resulted in any of the following outcomes:
Death
Life-threatening condition
Hospitalization or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Congenital anomaly/birth defect
Other medically important condition.
The relationship of an event to the study drug was determined by the investigator based on whether the AE could be reasonably explained as being caused by the study drug.</description>
          <population>The safety population included all randomized participants who received at least 1 dose of the study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation of study drug due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to drug-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug until 28 days after end of treatment; Day 35 to 42</time_frame>
      <group_list>
        <group group_id="E1">
          <title>S-649266</title>
        </group>
        <group group_id="E2">
          <title>Imipenem/Cilastatin</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital ureteric anomaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Obstructive nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Urethrotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

